U.S. Sen. Tammy Baldwin
Press Release

U.S. Senator Tammy Baldwin Urges DEA to Lower Opioid Quotas to Combat Prescription Drug Abuse

After years of allowing skyrocketing opioid production, agency last year heeded senators’ call to lower quota

By - Jul 11th, 2017 02:19 pm

WASHINGTON, D.C. – Today, U.S. Senator Tammy Baldwin (D-WI) joined a group of fifteen senators, led by Dick Durbin (D-IL), in sending a letter to the Drug Enforcement Administration (DEA), urging the agency to better prevent painkillers from flooding the market by setting lower opioid production quotas for 2018. Last year, the DEA heeded the call from senators to address America’s opioid epidemic by reducing nearly all opioid quotas by 25 percent or more. This was the first reduction of its kind in over twenty years, but DEA-approved opioid production volumes remain troublingly high—including 55 percent higher oxycodone levels in 2017 than in 2007.

“As the gatekeeper for how many opioids are allowed to be sold legally every year in the United States, we commend DEA on taking initial steps last year to lower production quotas for the first time in a generation,” wrote the senators.  “However, the 2017 production quota levels for numerous schedule II opioids remain dramatically higher than they were a decade ago.  Further reductions, through DEA’s existing quota-setting authority, are necessary to rein in this epidemic.”

The senators also pressed the agency to improve transparency in its quota-setting process by providing an explanation of how it reaches a determination and publishing quotas granted to individual manufacturers of schedule II opioids.

Senators Sherrod Brown (D-OH), Amy Klobuchar (D-MN), Edward J. Markey (D-MA), Joe Manchin (D-WV), Angus King (I-ME), Dianne Feinstein (D-CA), Claire McCaskill (D-MO), Patrick Leahy (D-VT), Jeanne Shaheen (D-NH), Kirsten Gillibrand (D-NY), Catherine Cortez Masto (D-NV), Maggie Hassan (D-NH), Richard Blumenthal (D-CT), and Al Franken (D-MN) also signed today’s letter.

Between 1993 and 2015, the DEA allowed production of oxycodone to increase 39-fold, hydrocodone to increase 12-fold, hydromorphone to increase 23-fold, and fentanyl to increase 25-fold. As a result, the number of opioid pain relievers dispensed in the United States has skyrocketed over the last two decades – from 76 million prescriptions in 1991 to more than 245 million prescriptions in 2014. The increase in opioid-related overdose deaths has mirrored the dramatic rise in opioid prescribing, with more than 33,000 deaths in 2015.

Full text of the letter is available here.

NOTE: This press release was submitted to Urban Milwaukee and was not written by an Urban Milwaukee writer. While it is believed to be reliable, Urban Milwaukee does not guarantee its accuracy or completeness.

Mentioned in This Press Release

Recent Press Releases by U.S. Sen. Tammy Baldwin

Report: Wisconsin Hospitals Will Lose $264 Million Annually Under Republicans’ Budget Bill

Baldwin voted against bill that will kick over 270,000 Wisconsinites off their healthcare

Baldwin, Murkowski Introduce Bipartisan Bill to Protect Our Shoreline Communities

Bill reauthorizes program that provides essential data and resources for coastal communities to protect against storms, boost safety, and plan for the future

Baldwin Statement on House Passage of Republicans’ Budget Bill That Guts Medicaid, Raises Costs for Families

In Wisconsin, the bill will terminate at least 250,000 people’s health care, reduce or eliminate 90,000 Wisconsinites’ food assistance, and threaten to close rural hospitals

Comments

  1. J.T. says:

    The 25% opioid reduction is the built-in cushion over and above the authorized amounts.

Leave a Reply

You must be an Urban Milwaukee member to leave a comment. Membership, which includes a host of perks, including an ad-free website, tickets to marquee events like Summerfest, the Wisconsin State Fair and the Florentine Opera, a better photo browser and access to members-only, behind-the-scenes tours, starts at $9/month. Learn more.

Join now and cancel anytime.

If you are an existing member, sign-in to leave a comment.

Have questions? Need to report an error? Contact Us